TheraDep Technologies has appointed Dr. Richard Eglen to its Board of Directors to help guide the company’s strategic growth and technology commercialization.
Key Highlights
- Industry Expertise: Dr. Eglen brings over 40 years of executive experience from major life-science and diagnostic leaders, including Corning, PerkinElmer (Revvity), and Roche.
- Strategic Role: His background in building successful life-science platforms will be used to scale TheraDep’s global partnerships and advance its proprietary BioDep™ deposition technology.
- Technology Validation: Dr. Eglen highlighted TheraDep’s single-step nano-meter deposition process as a “breakthrough” for the endovascular, medical device, and life-science sectors.
Impact on TheraDep
This appointment strengthens TheraDep’s governance as it moves into an intensive phase of commercial deployment for its automated biologic coating processes.
